Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.

Issue 3, 2018
Previous Article Next Article

Nanoscale delivery systems for cancer immunotherapy

Author affiliations


Increased understanding of tumor immunology has prompted rapid development of cancer immunotherapy in the past few years. The recent clinical success of immunotherapeutic approaches, such as immune checkpoint blockade and chimeric antigen receptor T cells, demonstrates their potential as a “cancer terminator”. Nevertheless, strategies to improve the overall efficiency and to reduce the side effects of immunotherapy are highly demanded. Nano-delivery systems hold great promise in biomedical applications due to their unique physiochemical properties and advantages in efficient tissue-specific delivery, enhanced cellular uptake and responsiveness to physiological and environmental stimuli. Immuno-nanomedicine opens a new field in cancer treatment and has attracted broad interest. In this review, we present recent advances in the field of cancer immunotherapy and focus on the nanocarrier-mediated delivery of immunomodulators as well as manipulation of immune cells. Applications of various types of nanomaterials (inorganic, polymers, liposomes, DNA-based, biomimetic and bio-derived nanoparticles) are summarized. Challenges and opportunities of nanovehicles in cancer immuno-oncology are also discussed.

Graphical abstract: Nanoscale delivery systems for cancer immunotherapy

Back to tab navigation

Article information

20 Nov 2017
12 Feb 2018
First published
12 Feb 2018

Mater. Horiz., 2018,5, 344-362
Article type
Review Article

Nanoscale delivery systems for cancer immunotherapy

Z. Wang, W. Liu, J. Shi, N. Chen and C. Fan, Mater. Horiz., 2018, 5, 344
DOI: 10.1039/C7MH00991G

Social activity

Search articles by author